InsiderTrades.com logo
War on Elon Escalates…
From Porter & Company   |   Ad
Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
Click here to learn how you can benefit from its widespread distribution.

Michael MacLean Biography and Net Worth

Chief Financial and Chief Business Officer of Avidity Biosciences
  • Phone
  • Email
  • Website


Michael MacLean, Chief Financial and Chief Business Officer, joined Avidity Biosciences Inc in 2020. Mike brings more than 30 years of strategic financial leadership within life sciences and other industries to Avidity, with deep experience in funding biotechnology companies to advance novel therapies in the rare and orphan disease space. In addition, his past roles included working with growing global commercial teams to support multiple product launches.  Prior to Avidity, Mike served as Chief Financial Officer of Akcea Therapeutics, Inc., another company focused on RNA therapies, where he led the buildout of Akcea’s financial and commercial infrastructure, and also served as Chief Financial Officer of PureTech Health, plc. In addition, he held the position of Chief Accounting Officer of Biogen Inc. where he led the company’s worldwide finance operations. Mike currently serves as member of the board of directors at Verve Therapeutics.

What is Michael F. MacLean's net worth?

The estimated net worth of Michael F. MacLean is at least $1.96 million as of June 12th, 2024. Mr. MacLean owns 44,093 shares of Avidity Biosciences stock worth more than $1,961,257 as of September 21st. This net worth approximation does not reflect any other assets that Mr. MacLean may own. Additionally, Mr. MacLean receives an annual salary of $674,740.00 as Chief Financial and Chief Business Officer at Avidity Biosciences. Learn More about Michael F. MacLean's net worth.

How old is Michael F. MacLean?

Mr. MacLean is currently 58 years old. There are 7 older executives and no younger executives at Avidity Biosciences. The oldest executive at Avidity Biosciences is Dr. Frank P. McCormick Ph.D., Scientific Founder & Member of Scientific Advisory Board, who is 74 years old. Learn More on Michael F. MacLean's age.

What is Michael F. MacLean's salary?

As the Chief Financial and Chief Business Officer of Avidity Biosciences, Inc., Mr. MacLean earns $674,740.00 per year. There are 2 executives that earn more than Mr. MacLean. The highest earning executive at Avidity Biosciences is Ms. Sarah Boyce, President, CEO & Director, who commands a salary of $998,880.00 per year. Learn More on Michael F. MacLean's salary.

How do I contact Michael F. MacLean?

The corporate mailing address for Mr. MacLean and other Avidity Biosciences executives is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. Avidity Biosciences can also be reached via phone at 858-401-7900 and via email at [email protected]. Learn More on Michael F. MacLean's contact information.

Has Michael F. MacLean been buying or selling shares of Avidity Biosciences?

Michael F. MacLean has not been actively trading shares of Avidity Biosciences during the last quarter. Most recently, Michael F. Maclean sold 104,245 shares of the business's stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $35.72, for a transaction totalling $3,723,631.40. Following the completion of the sale, the chief financial officer now directly owns 44,093 shares of the company's stock, valued at $1,575,001.96. Learn More on Michael F. MacLean's trading history.

Who are Avidity Biosciences' active insiders?

Avidity Biosciences' insider roster includes Sarah Boyce (President & CEO), W. Flanagan (Insider), Arthur Levin (Insider), and Michael MacLean (Chief Financial and Chief Business Officer). Learn More on Avidity Biosciences' active insiders.

Are insiders buying or selling shares of Avidity Biosciences?

During the last year, insiders at the biotechnology company sold shares 23 times. They sold a total of 737,815 shares worth more than $23,466,751.75. The most recent insider tranaction occured on September, 19th when Director Arthur A Levin sold 5,000 shares worth more than $228,650.00. Insiders at Avidity Biosciences own 3.7% of the company. Learn More about insider trades at Avidity Biosciences.

Information on this page was last updated on 9/19/2024.

Michael F. MacLean Insider Trading History at Avidity Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/12/2024Sell104,245$35.72$3,723,631.4044,093View SEC Filing Icon  
5/14/2024Sell75,000$28.28$2,121,000.0044,093View SEC Filing Icon  
3/13/2024Sell40,000$24.52$980,800.0044,093View SEC Filing Icon  
1/22/2024Sell1,616$10.13$16,370.0816,884View SEC Filing Icon  
See Full Table

Michael F. MacLean Buying and Selling Activity at Avidity Biosciences

This chart shows Michael F Maclean's buying and selling at Avidity Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Avidity Biosciences Company Overview

Avidity Biosciences logo
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $44.48
Low: $44.05
High: $46.09

50 Day Range

MA: $43.82
Low: $40.46
High: $48.14

2 Week Range

Now: $44.48
Low: $4.82
High: $48.80

Volume

4,998,430 shs

Average Volume

1,362,889 shs

Market Capitalization

$4.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89
War on Elon Escalates…
From Porter & Company   |   Ad
Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
Click here to learn how you can benefit from its widespread distribution.